Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 4,752 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 86,975 shares of the biopharmaceutical company’s stock after selling 4,752 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Regeneron Pharmaceuticals were worth $67,080,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Marietta Wealth Management LLC grew its stake in Regeneron Pharmaceuticals by 1.1% in the 4th quarter. Marietta Wealth Management LLC now owns 12,160 shares of the biopharmaceutical company’s stock worth $9,386,000 after acquiring an additional 135 shares in the last quarter. HB Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 36.3% during the fourth quarter. HB Wealth Management LLC now owns 2,427 shares of the biopharmaceutical company’s stock valued at $1,874,000 after acquiring an additional 646 shares in the last quarter. Caprock Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 14.8% in the fourth quarter. Caprock Group LLC now owns 2,901 shares of the biopharmaceutical company’s stock valued at $2,239,000 after purchasing an additional 373 shares during the period. Hobbs Group Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $243,000. Finally, M&T Bank Corp grew its stake in Regeneron Pharmaceuticals by 193.9% in the fourth quarter. M&T Bank Corp now owns 15,689 shares of the biopharmaceutical company’s stock worth $12,110,000 after purchasing an additional 10,350 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on REGN. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Evercore increased their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Finally, Piper Sandler began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an “overweight” rating and a $875.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $811.96.

Regeneron Pharmaceuticals Stock Down 0.1%

NASDAQ:REGN opened at $746.58 on Thursday. The company’s 50-day simple moving average is $764.22 and its 200-day simple moving average is $729.68. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The stock has a market capitalization of $78.93 billion, a P/E ratio of 17.96, a P/E/G ratio of 1.66 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business posted $12.07 EPS. Regeneron Pharmaceuticals’s revenue was up 2.5% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.2 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,774 shares of company stock valued at $2,942,738 in the last quarter. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.